ReviewTherapeutic advances in hematology2019

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.

Robert M Stern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.